Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III trial of eflornithine + sulindac versus either agent alone in familial adenomatous polyposis
2012-000427-41Phase 3Completed
- Sponsor
- Cancer Prevention Pharmaceuticals, Inc.
- Start
- Jul 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Colonic Adenomatous Polyposis comparing eflornithine + sulindac, eflornithine alone and sulindac alone (3 arms). Primary endpoint: First occurrence of any FAP-related event. Started Jul 2013; status: completed.
02
Drugs
eflornithinesulindac
03
Conditions
Colonic Adenomatous Polyposis
Beyond the preview
Go deeper on 2012-000427-41.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-000427-41.